Edison Group Expands U.S. Team With Two New Senior Appointments
January 28, 2019 09:32 ET
|
Edison Group
Hires Bring Four Decades of Investor Relations Experience and Strengthen Edison’s Roadshow Capability in North America NEW YORK, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Edison Group, a leading investor...
Edison issues initiation on Destiny Pharma (DEST)
September 04, 2018 12:04 ET
|
Edison Group
LONDON, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Destiny Pharma is a virtual antimicrobial discovery company in Phase II clinical studies in the US. Destiny’s XF series of antimicrobial agents are novel,...
Edison issues outlook on Ultra Electronics (ULE)
August 06, 2018 09:51 ET
|
Edison Group
LONDON, Aug. 06, 2018 (GLOBE NEWSWIRE) -- The overall picture of improving global defence spending supports a return to organic growth for UItra. This is already reflected in the uplift seen in the...
Edison issues update on Celyad (CYAD)
August 02, 2018 11:04 ET
|
Edison Group
LONDON, Aug. 02, 2018 (GLOBE NEWSWIRE) -- The FDA’s sign off on Celyad’s first clinical trial design for its allogeneic NRK CAR T-cell therapy (CYAD-101) is an important milestone. The study,...
Edison issues outlook on paragon (PGN)
August 02, 2018 10:35 ET
|
Edison Group
LONDON, Aug. 02, 2018 (GLOBE NEWSWIRE) -- paragon’s continued strong growth is driven by the Electromobility division (Voltabox) and the smaller Mechanics division. With the Electronics division...
Edison issues outlook on Oryzon Genomics (ORY)
July 18, 2018 11:22 ET
|
Edison Group
LONDON, July 18, 2018 (GLOBE NEWSWIRE) -- The next year is shaping up to be transformative for Oryzon with two data readouts from Phase IIa trials with ORY-2001 in Alzheimer’s disease (AD) and...
Edison issues outlook on Transgene (TNG)
July 16, 2018 11:03 ET
|
Edison Group
LONDON, July 16, 2018 (GLOBE NEWSWIRE) -- Transgene develops virus-based product candidates for use in oncology and infectious diseases, its five clinical products are currently in 11 clinical...
Edison issues outlook on Basilea Pharmaceutica (BSLN)
July 16, 2018 06:02 ET
|
Edison Group
LONDON, July 16, 2018 (GLOBE NEWSWIRE) -- Basilea has successfully brought two anti-infective drugs to the market: Cresemba (severe mould infections) and Zevtera (bacterial infections). With the...
Edison issues update on ReNeuron Group (RENE)
July 13, 2018 11:44 ET
|
Edison Group
LONDON, July 13, 2018 (GLOBE NEWSWIRE) -- ReNeuron ended FY18 with a healthy cash balance and the 11 July announcement of an exclusivity agreement worth up to US$5m with a US specialty...
Edison issues outlook on Quantum Genomics (ALQGC)
July 13, 2018 07:42 ET
|
Edison Group
LONDON, July 13, 2018 (GLOBE NEWSWIRE) -- Quantum Genomics is a biopharmaceutical company investigating brain aminopeptidase A inhibitors, a new class of drug, for the treatment of hypertension and...